ProdIgY Biotech
Developer of avian-derived (IgY) antibody therapeutics focused on microbiome modulation of the gut–liver axis to treat liver diseases. The company develops oral, non-systemic, polyclonal antibody agents that selectively neutralize pathogenic gut microbes and microbial toxins (notably cytolysin-producing Enterococcus faecalis) with the goal of treating alcohol-associated hepatitis and other liver disorders. Pipeline programs include preclinical-to-clinical development candidates for alcohol-associated hepatitis, primary sclerosing cholangitis, and metabolic dysfunction-associated steatohepatitis.
Industries
N/A
Products
PRO-AH-001
Oral IgY-based therapy targeting cytolysin-producing Enterococcus faecalis and its toxin to reduce liver inflammation in alcohol-associated hepatitis.
PRO-AH-002
Pipeline candidate for alcohol-associated hepatitis (stage indicated in company pipeline).
PRO-PSC-001
Pipeline candidate targeting primary sclerosing cholangitis.
PRO-MSH-001
Pipeline candidate for metabolic dysfunction-associated steatohepatitis (MASH).
PRO-AH-001
Oral IgY-based therapy targeting cytolysin-producing Enterococcus faecalis and its toxin to reduce liver inflammation in alcohol-associated hepatitis.
PRO-AH-002
Pipeline candidate for alcohol-associated hepatitis (stage indicated in company pipeline).
PRO-PSC-001
Pipeline candidate targeting primary sclerosing cholangitis.
PRO-MSH-001
Pipeline candidate for metabolic dysfunction-associated steatohepatitis (MASH).
Expertise Areas
- IgY-based antibody therapeutics
- Microbiome-targeted therapies
- Preclinical development and translational research
- Microbiota-humanized animal models
Key Technologies
- Avian-derived IgY antibodies
- Polyclonal antibody production
- Microbiome profiling
- Oral, gut-localized biologic delivery